Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 201

1.

The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal revisited.

Cooper JS, Fortpied C, Gregoire V, Le QT, Pajak TF, Zhang QE, Bernier J.

Cancer. 2017 Jan 1;123(1):12-16. doi: 10.1002/cncr.30266. Epub 2016 Oct 11. No abstract available.

2.

EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer.

Knudsen ES, Dervishaj O, Kleer CG, Pajak T, Schwartz GF, Witkiewicz AK.

Cell Cycle. 2013 Jul 1;12(13):2042-50. doi: 10.4161/cc.25065. Epub 2013 Jun 6.

3.

Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression.

Knudsen ES, Pajak TF, Qeenan M, McClendon AK, Armon BD, Schwartz GF, Witkiewicz AK.

J Natl Cancer Inst. 2012 Dec 5;104(23):1825-36. doi: 10.1093/jnci/djs446. Epub 2012 Nov 28.

4.

Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS.

J Clin Oncol. 2013 Mar 1;31(7):845-52. doi: 10.1200/JCO.2012.43.6097. Epub 2012 Nov 26.

5.

Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck.

Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205. doi: 10.1016/j.ijrobp.2012.05.008. Epub 2012 Jun 30.

6.

A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer.

Rondeau V, Pignon JP, Michiels S; MACH-NC collaborative Group.

Stat Methods Med Res. 2015 Dec;24(6):711-29. doi: 10.1177/0962280211425578. Epub 2011 Oct 23.

PMID:
22025414
7.

Hyperfractionated or accelerated radiotherapy for head and neck cancer.

Baujat B, Bourhis J, Blanchard P, Overgaard J, Ang KK, Saunders M, Le Maître A, Bernier J, Horiot JC, Maillard E, Pajak TF, Poulsen MG, Bourredjem A, O'Sullivan B, Dobrowsky W, Andrzej H, Skladowski K, Hay JH, Pinto LH, Fu KK, Fallai C, Sylvester R, Pignon JP; MARCH Collaborative Group.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD002026. doi: 10.1002/14651858.CD002026. Review.

PMID:
21154350
8.

Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.

Rink L, Skorobogatko Y, Kossenkov AV, Belinsky MG, Pajak T, Heinrich MC, Blanke CD, von Mehren M, Ochs MF, Eisenberg B, Godwin AK.

Mol Cancer Ther. 2009 Aug;8(8):2172-82. doi: 10.1158/1535-7163.MCT-09-0193. Epub 2009 Aug 11.

9.

Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03.

Le QT, Harris J, Magliocco AM, Kong CS, Diaz R, Shin B, Cao H, Trotti A, Erler JT, Chung CH, Dicker A, Pajak TF, Giaccia AJ, Ang KK.

J Clin Oncol. 2009 Sep 10;27(26):4281-6. doi: 10.1200/JCO.2008.20.6003. Epub 2009 Aug 10.

10.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group.

Radiother Oncol. 2009 Jul;92(1):4-14. doi: 10.1016/j.radonc.2009.04.014. Epub 2009 May 14.

PMID:
19446902
11.

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.

Michiels S, Le Maître A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, Vermorken JB, Budach W, Pajak TF, Ang KK, Bourhis J, Pignon JP; MARCH and MACH-NC Collaborative Groups.

Lancet Oncol. 2009 Apr;10(4):341-50. doi: 10.1016/S1470-2045(09)70023-3. Epub 2009 Feb 24.

PMID:
19246242
12.

Treatment of head and neck cancer.

Trotti A 3rd, Pajak TF, Ridge JA.

N Engl J Med. 2008 Mar 6;358(10):1076; author reply 1077-8. No abstract available.

PMID:
18326079
13.

Emotional well-being does not predict survival in head and neck cancer patients: a Radiation Therapy Oncology Group study.

Coyne JC, Pajak TF, Harris J, Konski A, Movsas B, Ang K, Watkins Bruner D; Radiation Therapy Oncology Group.

Cancer. 2007 Dec 1;110(11):2568-75.

14.

Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis.

Siddiqui F, Pajak TF, Watkins-Bruner D, Konski AA, Coyne JC, Gwede CK, Garden AS, Spencer SA, Jones C, Movsas B.

Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):353-60. Epub 2007 Sep 24.

PMID:
17889449
15.

Microvessel density >or=60 does not predict for outcome after radiation treatment for locally advanced head and neck squamous cell carcinoma: results of a correlative study from the Radiation Therapy Oncology Group (RTOG) 90-03 Trial.

Calvin DP, Hammond ME, Pajak TF, Trotti AM, Meredith RF, Rotman M, Jones CU, Byhardt RW, Demas WF, Ang KK, Fu KK; Radiation Therapy Oncology Group 90-03 Trial.

Am J Clin Oncol. 2007 Aug;30(4):406-19.

PMID:
17762442
16.

Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03).

Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, Cmelak AJ, Schulsinger A, Fu KK; Radiation Therapy Oncology Group.

Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1008-17. Epub 2007 Aug 23.

PMID:
17716826
17.

TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group.

Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK, Curran W.

Lancet Oncol. 2007 Jul;8(7):613-24.

PMID:
17543584
18.

Catalytic destruction of 1,2-dichlorobenzene on V2O5-WO3/Al2O3-TiO2 catalyst.

Wielgosiński G, Grochowalski A, Machej T, Pajak T, Cwiakalski W.

Chemosphere. 2007 Apr;67(9):S150-4. Epub 2007 Jan 19.

PMID:
17239926
19.

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maître A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP; Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group.

Lancet. 2006 Sep 2;368(9538):843-54. Review.

PMID:
16950362
20.

Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials.

Konski AA, Pajak TF, Movsas B, Coyne J, Harris J, Gwede C, Garden A, Spencer S, Jones C, Watkins-Bruner D; Radiation Therapy Oncology Group.

J Clin Oncol. 2006 Sep 1;24(25):4177-83.

PMID:
16943534

Supplemental Content

Loading ...
Support Center